



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

UTRECHT UNIVERSITY LICENSES METADRUG FROM GENEGO FOR DRUG INNOVATION

St. Joseph, MI. November 20th, 2007 –GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that Utrecht University will be using MetaDrug in their prestige master program for drug innovation. MetaDrug is designed for predicting biological effects such as indications, toxicity and off-target effects for new compounds structures. Its content includes xenobiotics with known activity, endogenous metabolites and reactions, as well as pathways, networks and diseases which are important for knowledge-based drug discovery. Our integration to Elsevier MDL's Discovery Gate also helps find more information about the compounds of interest in patent databases and clinical trial databases.

“Our research students of drug innovation should learn to see the big picture as soon as possible, in order to become effective drug researchers. MetaDrug is state-of-the-art, but still very accessible to the novice user,” said Dr Ed Moret. “We really like the support and training they have offered to our students.”

“GeneGo is very serious about including MetaDrug in academic environments especially for teaching,” said Julie Bryant, Vice President of Business Development for GeneGo. “Academia pushes the limits of MetaDrug which allows us to further adapt it for new areas of medicinal chemistry and they publish new applications that we may not even have thought of using it in such a way.”

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.5™, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.5™ is designed for prediction of human metabolism, toxicity and biological effects for novel

small molecules compounds. MetaBase™ represents the knowledge base for MetaCore. For more information, please visit the company's web site at www.genego.com

MetaCore™, MetaBase™, MetaDrug™, MetaLink™, MetaDiscovery™, MetaTox™ and MetaMiner™, 1-2-3 Workflow™ are trademarks of GeneGo, Inc.